Traders should monitor uptake of the DecisionDx-Melanoma test in clinical practice following this high-quality prospective validation. The data support expanded use, especially in early-stage melanoma, which could drive volume and reimbursement momentum. The upcoming webcast on March 23 may provide further commercial insights.
Price Chart
Executive Summary
Castle Biosciences announced publication of data from a large prospective study showing its DecisionDx-Melanoma i31-SLNB test accurately identifies melanoma patients with less than 5% risk of sentinel lymph node (SLN) positivity, enabling clinicians to safely forgo SLNB in low-risk cases. The study demonstrated a 2.6% observed SLN positivity rate in patients predicted to be low-risk and a 97.8% three-year recurrence-free survival rate, outperforming traditional staging and other gene expression tests.
Key Facts
- Prospective, multicenter study of 912 patients with T1–T4 cutaneous melanoma across 30 U.S. centers
- Patients predicted by i31-SLNB to have <5% risk of SLN positivity had a 2.6% observed positivity rate
- Patients with >10% predicted risk had a 21.4% observed positivity rate (8.2x higher)
- In T1b–T2a tumors, SLN positivity was only 1.4% in those predicted <5% risk
- Low-risk patients had 97.8% three-year recurrence-free survival (RFS)
- i31-SLNB showed TN:FN ratio of 55:1 in T1–T2a and 73:1 in T1b–T2a, exceeding NCCN’s 19:1 benchmark
- Outperformed other GEP tests like CP-GEP, which reported lower TN:FN ratios (15:1)
Financial Impact
Potential revenue growth from increased test adoption due to strong clinical validation; no direct financial figures disclosed
Risk Factors
- Forward-looking statements about reduced procedures and cost savings are not guaranteed
- Adoption depends on payer reimbursement and physician behavior, not just clinical data
- Recent insider selling ($303K in 30 days) may indicate caution despite positive data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255641 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $33.19 $33.08 | ▼ −0.33% | ▲ +0.19% | $33.30 (+0.33%) |
Oct 5, 2026 21d ago | 144 | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.30 (−0.18%) |
Oct 5, 2026 21d ago | Insider Cluster | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.30 (−0.18%) |
Sep 23, 2026 4w ago | Insider Cluster | $35.19 $35.81 | ▼ −1.76% | ▼ −1.22% | $33.30 (+5.37%) |
Sep 16, 2026 5w ago | Insider Cluster | $36.78 $35.34 | ▼ −3.92% | ▼ −4.04% | $33.30 (−9.46%) |
Sep 11, 2026 6w ago | 144 | $33.44 $35.50 | ▲ +6.16% | ▲ +6.62% | $33.30 (−0.42%) |
Sep 3, 2026 7w ago | Insider Cluster | $32.91 $32.76 | ▲ +0.46% | ▼ −0.09% | $33.30 (−1.19%) |
Sep 2, 2026 7w ago | Insider Cluster | $32.65 $32.91 | ▲ +0.80% | ▲ +1.18% | $33.30 (+1.99%) |
Sep 1, 2026 7w ago | Insider Cluster | $33.42 $32.65 | ▼ −2.30% | ▼ −3.35% | $33.30 (−0.36%) |
Aug 27, 2026 8w ago | Insider Cluster | $33.50 $33.03 | ▼ −1.40% | ▼ −1.10% | $33.30 (−0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers